Quebec-based cannabis firm HEXO (TSX:HEXO,NYSE:HEXO) announced that CFO Michael Monahan stepped down from his executive role on Friday (October 4) after taking the position in May.

In a statement released shortly after trading hours on Friday, the former HEXO executive said he decided to leave the firm for family reasons, but will stay on as a consultant during the transition period.


“It has become apparent that this job requires me to spend the majority of my time in Gatineau and in Ottawa,” said Monahan. “This isn’t possible for me at this time given my family’s needs, and so I have decided to resign.”

Company shares fell 5.7 percent after trading hours on Friday, opening at C$5.11 on Monday (October 7).

In late May, Monahan’s appointment as CFO also came along with the establishment of HEXO USA in Delaware to help formalize the company’s presence in the US.

Monahan has been succeeded by Stephen Burwash, former vice president of strategic finance at HEXO. Burwash previously held the role of interim CFO prior to Monahan’s appointment after HEXO’s then-CFO Ed Chaplin confirmed he would also be transitioning out of the company.

The abrupt departure of Monahan raised some questions in the market about what’s happening behind the scenes at the marijuana producer.

It has also resulted in Bank of America Merrill Lynch downgrading the stock to a price target of C$4, less than half of its previous price target of C$9.

According to Bloomberg, Merrill Lynch analyst Christopher Carey wrote in a note to investors that there is no real way to know the expectations Monahan faced when he came into the role; nevertheless, his hasty resignation is a “concerning” marker of the inner workings of the company.

“We think it’s reasonable to assume the corporate finance organization was less developed than what Monahan had realized, perhaps indicating there remains much work to professionalizing said organization than what he (or the Street) fully appreciated,” wrote Carey.

The company saw another drop after the June release of its third quarter results, which missed the mark for some analysts.

HEXO reported C$13 million in net revenue for the period, up significantly from C$1.2 million in the same quarter last year, but BNN Bloomberg said that analysts expected revenues of C$14 million.

In a note to clients, RBC Capital Markets analyst Douglas Miehm said HEXO’s results were “a little light” when compared to estimates. Miehm did go on to note that the variance between RBC’s estimate and HEXO’s quarterly report was driven by the company’s performance in the medical business; adult-use segment results were in line with the RBC’s expectations.

Analyst consensus on TipRanks has the stock listed as a “moderate sell” with a price target of C$6.42, representing about a 26 percent upside over the current share price.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Jason Mitchell Co-Founder, Director and Chief Executive Officer, HempFusion Wellness Inc. (“HempFusion” or the “Company”) (TSX: CBD.U), and his team joined David Chelich Sector Head, Global Energy and Diversified Industries, TMX Group, to celebrate the Company’s new listing on Toronto Stock Exchange and open the market.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, which is managed by Horizons ETF Management.

The Horizons Psychedelic Stock Index ETF index is expected to start trading on Tuesday, January 26, under the ticker PSYK on the NEO exchange.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the closing of its previously announced overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for total gross proceeds of approximately US$125 million.

The Offered Securities were offered in each of the Provinces of Canada, other than Québec, pursuant to a prospectus supplement dated January 19, 2021 to the Company’s base shelf prospectus dated July 25, 2019 (collectively, the “Prospectus”) and in the United States on a private placement basis to “qualified institutional buyers” pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the ” U.S. Securities Act “).

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (FWB:8OO) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, will celebrate the Company’s listing on the Toronto Stock Exchange (“TSX”) by virtually ringing the TSX opening bell at 9:30 a.m. ET today. As previously announced, HempFusion completed its $17,000,000 initial public offering and commenced trading on the TSX on January 6, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210122005074/en/

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

 Numinus Wellness Inc. (” Numinus ” or the ” Company “) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that the TSX Venture Exchange (” TSXV “) has accepted for listing the 12,683,925 warrants (the ” Warrants “) issued pursuant to the Company’s previously announced prospectus offering that closed on December 29, 2020 .

Keep reading... Show less